关于公司
Avisi Technologies develops a nanotechnology-enabled defense against blindness from glaucoma. Avisi's product, VisiPlate, is a next-generation aqueous shunt that aims to treat mid to late-stage glaucoma. It is 20x thinner than a human hair. VisiPlate leverages an ultrathin nanoplate and its insertion procedure reduces operating time and makes follow-up care easier. VisiPlate is made of alumina, an implant material that has been used in hip replacements. Avisi Technologies is headquartered in Philadelphia, Pennsylvania.
US
未知
未验证公司
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论